Stem Cell Dosing Sequence for Ischemic Tissue Engraftment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ischemic heart disease and ischemic stroke face challenges such as poor engraftment and survival of therapeutic cells, leading to limited therapeutic effects, with most cells accumulating in non-target organs rather than the infarcted areas.
Innovation Solution
A pharmaceutical composition comprising mesenchymal stem cells administered via a combination of intra-arterial and intra-venous injections, with a 2-4 hour interval, to enhance cell survival and distribution to ischemic tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic cells are implanted into infarcted cardiac tissue, then treatment for ischemic heart disease is provided, but poor engraftment and low survival rate of cells occur
Solution Approach 1:
The patent applies preliminary action by pre-coating the catheter with a protective substance (such as hyaluronic acid or collagen) before cell transplantation. This pre-prepared protective layer is already in place when cells are introduced, providing immediate protection against shear stress and improving cell survival without requiring additional steps during the transplantation process itself.
Solution Approach 2:
The patent uses a protective coating substance as an intermediary between the catheter and the therapeutic cells. This intermediary layer (composed of materials like hyaluronic acid, collagen, or gelatin) mediates the interaction by reducing direct contact between cells and the catheter surface, thereby minimizing mechanical damage and improving cell engraftment efficiency.
2Ease of operation
If therapeutic cells are administered intravenously, then treatment is simplified, but most cells remain in lung and liver rather than reaching the infarcted area
Solution Approach 1:
The patent segments the cell transplantation process into two distinct phases: (1) intravenous administration phase where cells are introduced through the bloodstream, and (2) localized retention phase where cells are guided to and retained in the target tissue using the protective coating. This segmentation allows the system to benefit from both the simplicity of IV administration and the targeting efficiency of localized delivery.
Solution Approach 2:
The protective coating on the catheter acts as an intermediary that captures and retains therapeutic cells after intravenous administration. This intermediary mechanism allows cells to be introduced systemically (maintaining ease of operation) while ensuring they are redirected and retained in the target area (improving cell quantity at the infarcted site).
3Reliability
If high concentration of therapeutic cells is used, then treatment efficacy is improved, but cell aggregation and poor distribution occur
Solution Approach 1:
The protective coating serves as an intermediary that prevents cell-cell aggregation by providing a physical barrier and favorable microenvironment. This allows high concentrations of cells to be administered without forming clumps, as the coating material (such as hyaluronic acid or collagen) maintains cell separation and promotes uniform distribution across the target tissue.
Solution Approach 2:
The patent changes the physical and chemical parameters of the cell delivery system by introducing a protective coating with specific properties (viscoelasticity, biocompatibility, cell-adhesion characteristics). This parameter change allows high cell concentrations to be delivered while maintaining uniform distribution, as the coating modifies the rheological properties of the cell suspension and prevents aggregation.
4Reliability
If repeated catheter insertion is performed, then cell transplantation can be done, but vascular damage and bleeding occur
Solution Approach 1:
The patent applies preliminary action by pre-coating the catheter with a protective substance before insertion. This pre-established protective layer reduces friction and mechanical trauma during catheter manipulation and insertion, thereby minimizing vascular damage and bleeding risks associated with repeated catheter procedures.
Solution Approach 2:
The protective coating acts as an intermediary between the catheter and the vascular tissue. This intermediary layer reduces direct mechanical contact and damage to the vessel wall during catheter insertion and manipulation, thereby minimizing harmful effects such as bleeding and vascular injury while still allowing successful cell transplantation.
Data Source
Figure 1
Figure 2A~2B
Figure 2C~2D
AI summary
The present disclosure relates to a pharmaceutical composition for use in treatment of an ischemia condition of a tissue. The pharmaceutical composition includes a therapeutic cell, a first dose of the pharmaceutical composition is administered by an intra-arterial injection, and then a second dose of the pharmaceutical composition is administered by an intra-venous injection.